非小细胞肺癌循环肿瘤细胞PD-L1检测及临床应用

doi:10.3760/cma.j.cn371439-20250312-00110

国际肿瘤学杂志 ›› 2025, Vol. 52 ›› Issue (10): 641-645.doi: 10.3760/cma.j.cn371439-20250312-00110

非小细胞肺癌循环肿瘤细胞PD-L1检测及临床应用

宋紫嫣¹, 张文静¹, 王振丹², 赵治昆³, 马莹⁴, 李胜¹()

¹山东第一医科大学（山东省医学科学院）临床与基础医学院，济南 250117
²山东省肿瘤防治研究院（山东省肿瘤医院）肺外科，山东第一医科大学（山东省医学科学院），济南 250117
³山东第一医科大学第二附属医院肝胆外科，泰安 271099
⁴山东省药物研究院研发部，济南 250062

收稿日期:2025-03-12 修回日期:2025-07-05 出版日期:2025-10-08 发布日期:2025-11-12
通讯作者: 李胜 E-mail:sdywyjy@126.com

Detection of PD-L1 in circulating tumor cells of non-small cell lung cancer and its clinical applications

Song Ziyan¹, Zhang Wenjing¹, Wang Zhendan², Zhao Zhikun³, Ma Ying⁴, Li Sheng¹()

¹College of Clinical and Basic Medicine， Shandong First Medical University & Shandong Academy of Medical Sciences， Jinan 250117， China
²Department of Pulmonary Surgery， Shandong Cancer Hospital and Institute， Shandong First Medical University & Shandong Academy of Medical Sciences， Jinan 250117， China
³Department of Hepatobiliary Surgery， Second Affiliated Hospital of Shandong First Medical University， Tai'an 271099， China
⁴Department of Research and Development， Shandong Pharmaceutical Research Institute， Jinan 250062， China

Received:2025-03-12 Revised:2025-07-05 Online:2025-10-08 Published:2025-11-12
Contact: Li Sheng E-mail:sdywyjy@126.com

摘要/Abstract

摘要：

非小细胞肺癌（NSCLC）是全球发病率较高的恶性肿瘤，约占全部癌症新发病例的10.54%，严重威胁人类健康。由于免疫治疗在NSCLC患者中存在显著个体疗效差异，因此需寻找准确的检测指标以筛选适用人群、进行疗效监测并辅助判断预后。程序性死亡受体配体1（PD-L1）作为一种表达于肿瘤细胞表面和多种免疫细胞膜上的免疫抑制分子，可作为“伴随诊断”或“补充诊断”指导转移性NSCLC患者临床用药。由于组织PD-L1检测属于有创检查且其可靠性存在争议，因此通过循环肿瘤细胞等液体活检方式评估PD-L1表达将在NSCLC治疗反应和预后预测中发挥重要作用。

关键词: 癌，非小细胞肺, 肿瘤细胞，循环, B7-H1抗原, 检测技术

Abstract:

Non-small cell lung cancer （NSCLC） is a malignant tumor with a high global incidence rate， accounting for about 10.54% of all new cancer cases and posing a serious threat to human health. Due to significant individual variations in the efficacy of immunotherapy among NSCLC patients， it is necessary to identify accurate detection indicators to screen appropriate populations， monitor treatment efficacy， and assist in prognosis assessment. Programmed death-ligand 1 （PD-L1）， as an immunosuppressive molecule expressed on the surface of tumor cells and various immune cell membranes， can serve as a "companion diagnostic" or "supplementary diagnostic" tool to guide clinical treatment decisions for metastatic NSCLC patients. Given that tumor tissue PD-L1 testing is an invasive procedure and its reliability is still under debate， the assessment of PD-L1 expression via liquid biopsies， such as circulating tumor cells， will play a significant role in predicting treatment response and prognosis in NSCLC patients.

Key words: Carcinoma， non-small-cell lung, Neoplastic cells， circulating, B7-H1 antigen, Detection techniques

宋紫嫣, 张文静, 王振丹, 赵治昆, 马莹, 李胜. 非小细胞肺癌循环肿瘤细胞PD-L1检测及临床应用[J]. 国际肿瘤学杂志, 2025, 52(10): 641-645.

Song Ziyan, Zhang Wenjing, Wang Zhendan, Zhao Zhikun, Ma Ying, Li Sheng. Detection of PD-L1 in circulating tumor cells of non-small cell lung cancer and its clinical applications[J]. Journal of International Oncology, 2025, 52(10): 641-645.

参考文献 28

[1]	Li C, Lei S, Ding L, et al. Global burden and trends of lung cancer incidence and mortality[J]. Chin Med J (Engl), 2023, 136(13): 1583-1590. DOI: 10.1097/CM9.0000000000002529.
[2]	Parvez A, Choudhary F, Mudgal P, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment[J]. Front Immunol, 2023, 14: 1296341. DOI: 10.3389/fimmu.2023.1296341.
[3]	邓隽军, 赵大勇, 李淼. 免疫检查点抑制剂在非小细胞肺癌治疗中的不良反应及危险因素[J]. 国际肿瘤学杂志, 2023, 50(9): 564-568. DOI: 10.3760/cma.j.cn371439-20230404-00108.
[4]	Riely GJ, Wood DE, Ettinger DS, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(4): 249-274. DOI: 10.6004/jnccn.2204.0023.
[5]	Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(5): 497-530. DOI: 10.6004/jnccn.2022.0025.
[6]	Gompelmann D, Sarova P, Mosleh B, et al. PD-L1 assessment in lung cancer biopsies-pitfalls and limitations[J]. Int J Biol Markers, 2024, 39(1): 3-8. DOI: 10.1177/03936155231214273.
[7]	Ring A, Nguyen-Sträuli BD, Wicki A, et al. Biology,vulnerabilities and clinical applications of circulating tumour cells[J]. Nat Rev Cancer, 2023, 23(2): 95-111. DOI: 10.1038/s41568-022-00536-4.
[8]	Pantazaka E, Ntzifa A, Roumeliotou A, et al. PD-L1/pS6 in cir-culating tumor cells (CTCs) during osimertinib treatment in patients with non-small cell lung cancer (NSCLC)[J]. Biomedicines, 2022, 10(8): 1893. DOI: 10.3390/biomedicines10081893.
[9]	Ikeda M, Koh Y, Teraoka S, et al. Longitudinal evaluation of PD-L1 expression on circulating tumor cells in non-small cell lung cancer patients treated with nivolumab[J]. Cancers (Basel), 2021, 13(10): 2290. DOI: 10.3390/cancers13102290.
[10]	Sinoquet L, Jacot W, Quantin X, et al. Liquid biopsy and immuno-oncology for advanced nonsmall cell lung cancer[J]. Clin Chem, 2023, 69(1): 23-40. DOI: 10.1093/clinchem/hvac166.
[11]	Cheng Y, Wang T, Lv X, et al. Detection of PD-L1 expression and its clinical significance in circulating tumor cells from patients with non-small-cell lung cancer[J]. Cancer Manag Res, 2020, 12: 2069-2078. DOI: 10.2147/CMAR.S245425. pmid: 32256114
[12]	Janning M, Kobus F, Babayan A, et al. Determination of PD-L1 expression in circulating tumor cells of NSCLC patients and correlation with response to PD-1/PD-L1 inhibitors[J]. Cancers (Basel), 2019, 11(6): 835. DOI: 10.3390/cancers11060835.
[13]	Schehr JL, Schultz ZD, Warrick JW, et al. High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1[J]. PLoS One, 2016, 11(7): e0159397. DOI: 10.1371/journal.pone.0159397.
[14]	Liu Q, Zhao C, Jiang P, et al. Circulating tumor cells counts are associated with CD8⁺ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: a retrospective study[J]. Medicine (Baltimore), 2021, 100(29): e26674. DOI: 10.1097/MD.0000000000026674.
[15]	Dong J, Zhu D, Tang X, et al. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer[J]. PLoS One, 2019, 14(7): e0220306. DOI: 10.1371/journal.pone.0220306.
[16]	Cohen EN, Jayachandran G, Gao H, et al. Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally advanced non-small cell lung cancer[J]. Transl Lung Cancer Res, 2023, 12(1): 109-126. DOI: 10.21037/tlcr-22-314.
[17]	Ntzifa A, Strati A, Kallergi G, et al. Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients[J]. Sci Rep, 2021, 11(1): 2313. DOI: 10.1038/s41598-021-82068-9.
[18]	Rafli R, Harahap WA, Gondhowiardjo S, et al. Investigating radiotherapy effects on PD-L1 expression in circulating tumor cells: an exploratory study[J]. Asian Pac J Cancer Prev, 2024, 25(5): 1559-1566. DOI: 10.31557/APJCP.2024.25.5.1559.
[19]	Teo J, Mirenska A, Tan M, et al. A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry[J]. Future Sci OA, 2017, 3(4): FSO244. DOI: 10.4155/fsoa-2017-0079.
[20]	Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee[J]. J Thorac Oncol, 2020, 15(4): 499-519. DOI: 10.1016/j.jtho.2019.12.107. pmid: 31870882
[21]	Cai S, Deng Y, Wang Z, et al. Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis[J]. Front Oncol, 2023, 13: 1238332. DOI: 10.3389/fonc.2023.1238332.
[22]	Ilié M, Szafer-Glusman E, Hofman V, et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer[J]. Ann Oncol, 2018, 29(1): 193-199. DOI: 10.1093/annonc/mdx636. pmid: 29361135
[23]	Dall'Olio FG, Gelsomino F, Conci N, et al. PD-L1 expression in circulating tumor cells as a promising prognostic biomarker in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors[J]. Clin Lung Cancer, 2021, 22(5): 423-431. DOI: 10.1016/j.cllc.2021.03.005. pmid: 33849808
[24]	Zhou Q, Liu X, Li J, et al. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer[J]. Thorac Cancer, 2023, 14(5): 470-478. DOI: 10.1111/1759-7714.14767. pmid: 36630992
[25]	孔祥楠, 张茹, 宋欣新, 等. 非小细胞肺癌患者肺静脉血循环肿瘤细胞数量及程序性死亡受体配体-1表达与预后的关系[J]. 中华实用诊断与治疗杂志, 2021, 35(11): 1100-1103. DOI: 10.13507/j.issn.1674-3474.2021.11.006.
[26]	王伟. PD-L1在非小细胞肺癌外周血循环肿瘤细胞中的表达与分析[D]. 重庆: 重庆医科大学, 2021. DOI: 10.27674/d.cnki.gcyku. 2021.001000.
[27]	Dong J, Zhu D, Tang X, et al. Detection of circulating tumor cell molecular subtype in pulmonary vein predicting prognosis of stage Ⅰ-Ⅲ non-small cell lung cancer patients[J]. Front Oncol, 2019, 9: 1139. DOI: 10.3389/fonc.2019.01139.
[28]	Schehr JL, Sethakorn N, Schultz ZD, et al. Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA Ⅰ expression on circulating tumor cells from patients with non-small cell lung cancer[J]. Biomark Res, 2022, 10(1): 26. DOI: 10.1186/s40364-022-00370-8.

非小细胞肺癌循环肿瘤细胞PD-L1检测及临床应用

Detection of PD-L1 in circulating tumor cells of non-small cell lung cancer and its clinical applications

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王梦菊, 王霞. 白术内酯Ⅱ对结肠癌小鼠的抗肿瘤作用及免疫调节机制[J]. 国际肿瘤学杂志, 2025, 52(9): 545-553.
[2]	澈根, 乌日汗, 朱恬恬, 东丽. 非小细胞肺癌中cGAS-STING信号通路的作用机制及其靶向治疗策略[J]. 国际肿瘤学杂志, 2025, 52(9): 587-591.
[3]	赵芳, 姜国荣, 史淑月, 肖剑, 马少林, 李润浦. 阿特珠单抗联合安罗替尼治疗晚期非小细胞肺癌疗效观察[J]. 国际肿瘤学杂志, 2025, 52(8): 495-501.
[4]	张露莹, 梁嘉欣, 赵可雷, 袁晓晗, 刘亮博, 路平, 张桂芳, 张敏. 驱动基因阴性晚期NSCLC一线免疫及其联合治疗进展后不同二线治疗策略疗效的真实世界研究[J]. 国际肿瘤学杂志, 2025, 52(7): 419-425.
[5]	钟啸, 李步托, 王琳琳. ALK阳性NSCLC脑转移放疗的研究进展[J]. 国际肿瘤学杂志, 2025, 52(6): 374-378.
[6]	袁纯, 于雪松, 王孟超, 张韶, 黄彦博, 王超然, 孔凡铭, 陈立伟. EGFR ex20ins突变型晚期NSCLC靶向治疗新进展[J]. 国际肿瘤学杂志, 2025, 52(6): 382-387.
[7]	刘海燕, 张超. 基于CT影像加权组学评分构建非小细胞肺癌的免疫治疗疗效预测模型[J]. 国际肿瘤学杂志, 2025, 52(4): 202-208.
[8]	唐磊, 蔡宗佑, 常建华. RET原癌基因与非小细胞肺癌的研究现状[J]. 国际肿瘤学杂志, 2025, 52(4): 237-241.
[9]	杨胜军, 任江, 杨丹, 龙宇, 商群献. 非小细胞肺癌组织中miR-4262、NRG1的表达水平及临床意义[J]. 国际肿瘤学杂志, 2025, 52(3): 129-135.
[10]	来瑞鹤, 滕月, 戎剑, 盛丹丹, 耿羽智, 陈建新, 蒋冲, 丁重阳, 周正扬. 基于¹⁸F-FDG PET/CT原发灶影像组学的联合模型预测NSCLC淋巴结转移的价值[J]. 国际肿瘤学杂志, 2025, 52(3): 144-151.
[11]	王智颖, 盛立军. 外周血标志物在非小细胞肺癌免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(3): 180-185.
[12]	陈丹蕾, 邓隽军, 李淼. 循环肿瘤细胞在肺癌中的临床应用进展[J]. 国际肿瘤学杂志, 2025, 52(2): 119-123.
[13]	黄波, 汪鹏. 血清sCD163、IFN-γ联合TGF-β1对NSCLC患者放疗后发生放射性肺炎的早期预测价值[J]. 国际肿瘤学杂志, 2024, 51(9): 563-568.
[14]	王清北, 朱林, 吴正国. NSCLC肺内叶段淋巴结转移规律及全胸腔镜肺叶切除术中淋巴结清扫方式的选择[J]. 国际肿瘤学杂志, 2024, 51(9): 569-577.
[15]	倪国英, 黄骞, 梁洪享, 杨志勇, 丁颖丽. 晚期非小细胞肺癌患者血清miR-499、miR-362水平变化及与预后的关系分析[J]. 国际肿瘤学杂志, 2024, 51(8): 487-492.